SGLT2 inhibitors and GLP-1 receptor agonists were associated with fewer exacerbations of COPD in adults with type 2 diabetes. There was little difference between SGLT2 inhibitors and GLP-1 receptor ...

Metered-dose inhaler propellants have contributed a rising amount to greenhouse gases in the U.S. Emissions per inhaler declined slightly over the past decade, but an increase in annual prescription ...

Sotatercept, an activin-signaling inhibitor, reduces morbidity and mortality among patients with long-standing pulmonary arterial hypertension. Its effects in patients with pulmonary arterial ...

AstraZeneca's hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 ...

Please provide your email address to receive an email when new articles are posted on . Patients were assigned to either a 90-minute online, guided group singing session once a week for 12 weeks or ...

In patients with pulmonary arterial hypertension (PAH), the use of anticoagulants was not associated with improvement in overall survival, and these results were confirmed by an updated meta-analysis.

Jascayd is the first new IPF therapy approved in over 10 years, addressing a rare and serious disease with limited treatments. FDA approval was based on Phase III trials showing reduced FVC decline ...

The approval is the first in more than a decade for an idiopathic pulmonary fibrosis treatment. The FDA has approved nerandomilast (Jascayd; Boehringer Ingelheim) for the treatment of adults with ...

Credit: Boehringer Ingelheim. Nerandomilast reduces the expression of pro-fibrotic growth factors and inflammatory cytokines, commonly overexpressed in IPF. Findings showed nerandomilast led to a ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company, today announced new preclinical data demonstrating that its investigational therapy ...